- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00005372
Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study)
Study Overview
Status
Conditions
Detailed Description
BACKGROUND:
A finding from the Cholesterol Lowering Atherosclerosis Study (CLAS), a clinical trial, indicated that common carotid intima-media thickness responded more rapidly and more markedly to LDL-C lowering treatment than angiographic coronary stenosis or carotid roughness. New data from a primate model also showed ultrasound detection of intimal thickening in response to a hypercholesterolemic diet within twelve months. These findings suggest that carotid IMT is a reliable and rapidly responding marker of extent of atherosclerosis. However, less than a third of the observed therapeutic benefit on carotid IMT found in CLAS was explained by change in LDL-C and HDL-C, suggesting that related (or other) factors are more directly linked to atherogenic mechanisms. In addition, a Finnish epidemiologic study found that LDL-C was predicative of rate of progression in carotid IMT only in persons with high serum levels of (pro-oxidant) copper. . These and other data support a model of atherosclerosis in which intracellular accumulation of modified LDL is promoted/retarded by serum pro-oxidants/antioxidants.
DESIGN NARRATIVE:
The study tested the specific hypotheses that the positive association between rate of increase in carotid IMT and low density lipoprotein cholesterol (beta deltaIMT/LDL) was greater in persons with [1] higher levels of serum pro-oxidants (relative to persons with lower levels of serum pro-oxidants), [2] lower levels of serum antioxidants, [3] lower levels of dietary antioxidants; and [4] that regression of carotid IMT associated with smoking cessation would be detected in 30 months. Hypothesis were tested with the longitudinal observation of carotid IMT in Hispanic and non-Hispanic white women and men. The inclusion of Hispanics and women was motivated by their prevalence in the study population (18 percent Hispanic, 40 percent women), and by the then recent report that incidence of hospitalization for myocardial infarction was elevated in Hispanics. Seventy three persons from each of four ethnicity-sex groups aged 40-60 years (n-292), and 83 smokers and recent quitters (n-166) were recruited from employees in an ongoing study. Baseline blood, diet and potential confounder variables were related to 18 and 36 month (6, 12, 18, 24 and 30 month in smoker(s) changes in carotid IMT. Levels of antioxidant vitamins, including alpha-tocopherol, ascorbate, and beta carotene, in the plasma were measured at baseline. Plasma levels of negatively charged LDL were measured in a sub-sample of subjects with the most rapidly progressing common carotid intima-media thickness and in an age-sex matched subsample with the least rapidly progressing common carotid intima-media thickness. Finally, an ultrasound measurement of carotid arterial stiffness, another indicator of early atherosclerosis, was developed to address the role of blood pressure.
The Los Angeles Atherosclerosis Study (LAAS) has been renewed through February, 2004 to continue follow-up of the cohort for a total of seven years with two additional measures of arterial dysfunction, including endothelial function of the brachial artery and distensibility or stiffness of the common carotid artery.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- James Dwyer, University of Southern California
Publications and helpful links
General Publications
- Dwyer JH. Exposure to environmental tobacco smoke and coronary risk. Circulation. 1997 Sep 2;96(5):1367-9. No abstract available.
- Dwyer JH, Sun P, Kwong-Fu H, Dwyer KM, Selzer RH. Automated intima-media thickness: the Los Angeles Atherosclerosis Study. Ultrasound Med Biol. 1998 Sep;24(7):981-7. doi: 10.1016/s0301-5629(98)00069-6.
- Nordstrom CK, Dwyer KM, Merz CN, Shircore A, Dwyer JH. Work-related stress and early atherosclerosis. Epidemiology. 2001 Mar;12(2):180-5. doi: 10.1097/00001648-200103000-00009.
- Sun P, Dwyer KM, Merz CN, Sun W, Johnson CA, Shircore AM, Dwyer JH. Blood pressure, LDL cholesterol, and intima-media thickness: a test of the "response to injury" hypothesis of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2005-10. doi: 10.1161/01.atv.20.8.2005.
- Dwyer KM, Nordstrom CK, Bairey Merz CN, Dwyer JH. Carotid wall thickness and years since bilateral oophorectomy: the Los Angeles Atherosclerosis Study. Am J Epidemiol. 2002 Sep 1;156(5):438-44. doi: 10.1093/aje/kwf051.
- Bairey Merz CN, Dwyer J, Nordstrom CK, Walton KG, Salerno JW, Schneider RH. Psychosocial stress and cardiovascular disease: pathophysiological links. Behav Med. 2002 Winter;27(4):141-7. doi: 10.1080/08964280209596039.
- Nordstrom CK, Dwyer KM, Merz CN, Shircore A, Dwyer JH. Leisure time physical activity and early atherosclerosis: the Los Angeles Atherosclerosis Study. Am J Med. 2003 Jul;115(1):19-25. doi: 10.1016/s0002-9343(03)00242-0.
- Dwyer JH, Navab M, Dwyer KM, Hassan K, Sun P, Shircore A, Hama-Levy S, Hough G, Wang X, Drake T, Merz CN, Fogelman AM. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation. 2001 Jun 19;103(24):2922-7. doi: 10.1161/01.cir.103.24.2922.
- Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004 Jan 1;350(1):29-37. doi: 10.1056/NEJMoa025079.
- Wu H, Dwyer KM, Fan Z, Shircore A, Fan J, Dwyer JH. Dietary fiber and progression of atherosclerosis: the Los Angeles Atherosclerosis Study. Am J Clin Nutr. 2003 Dec;78(6):1085-91. doi: 10.1093/ajcn/78.6.1085.
- Burcelin R, Eddouks M, Kande J, Assan R, Girard J. Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats. Biochem J. 1992 Dec 1;288 ( Pt 2)(Pt 2):675-9. doi: 10.1042/bj2880675. Erratum In: Biochem J 1993 Feb 1;289(Pt 3):928.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4264
- R01HL049910 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Yongjian WuRecruitingValvular Heart DiseaseChina